Arvinas Inc

-4.20 (-4.35%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)4.86B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$106.12 Million
Adjusted EPS-$0.60
See more estimates
10-Day MA$93.11
50-Day MA$89.59
200-Day MA$76.18
See more pivots

Arvinas Inc Stock, NASDAQ:ARVN

5 Science Park, 395 Winchester Avenue, New Haven, Connecticut 06511
United States of America
Phone: +1.203.535.1456
Number of Employees: 179


Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.